Trade Grifols, S.A. - GRLS CFD
Add to favourite- Summary
- Historical Data
Spread | 0.08 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.022099% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.000123% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | EUR | ||||||||
Margin | 5% | ||||||||
Stock exchange | Spain | ||||||||
Commission on trade | 0% |
Prev. Close | 8.31 |
Open | 8.37 |
1-Year Change | -10.29% |
Day's Range | 8.32 - 8.4 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 24, 2024 | 8.31 | -0.40 | -4.59% | 8.71 | 8.71 | 8.29 |
Apr 23, 2024 | 8.57 | 0.30 | 3.63% | 8.27 | 8.76 | 8.20 |
Apr 22, 2024 | 8.26 | -0.12 | -1.43% | 8.38 | 8.45 | 8.16 |
Apr 19, 2024 | 8.37 | -0.02 | -0.24% | 8.39 | 8.44 | 8.19 |
Apr 18, 2024 | 8.60 | -0.22 | -2.49% | 8.82 | 8.84 | 8.52 |
Apr 17, 2024 | 8.77 | 0.13 | 1.50% | 8.64 | 8.91 | 8.59 |
Apr 16, 2024 | 8.59 | 0.14 | 1.66% | 8.45 | 8.63 | 8.27 |
Apr 15, 2024 | 8.49 | -0.03 | -0.35% | 8.52 | 8.67 | 8.43 |
Apr 12, 2024 | 8.56 | -0.25 | -2.84% | 8.81 | 8.85 | 8.44 |
Apr 11, 2024 | 8.68 | -0.38 | -4.19% | 9.06 | 9.22 | 8.38 |
Apr 10, 2024 | 9.08 | -0.41 | -4.32% | 9.49 | 9.64 | 8.98 |
Apr 9, 2024 | 9.35 | -0.22 | -2.30% | 9.57 | 9.62 | 9.34 |
Apr 8, 2024 | 9.41 | 0.38 | 4.21% | 9.03 | 9.47 | 8.99 |
Apr 5, 2024 | 8.99 | 0.22 | 2.51% | 8.77 | 9.24 | 8.69 |
Apr 4, 2024 | 9.03 | 0.24 | 2.73% | 8.79 | 9.04 | 8.68 |
Apr 3, 2024 | 8.73 | 0.36 | 4.30% | 8.37 | 8.73 | 8.30 |
Apr 2, 2024 | 8.37 | 0.08 | 0.97% | 8.29 | 8.45 | 8.21 |
Mar 28, 2024 | 8.30 | 0.04 | 0.48% | 8.26 | 8.40 | 8.22 |
Mar 27, 2024 | 8.24 | -0.07 | -0.84% | 8.31 | 8.38 | 8.17 |
Mar 26, 2024 | 8.26 | 0.15 | 1.85% | 8.11 | 8.27 | 8.08 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Grifols Company profile
About Grifols SA
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Grifols SA revenues decreased 8% to EUR4.93B. Net income before extraordinary items decreased 72% to EUR182.8M. Revenues reflect Bioscience segment decrease of 10% to EUR3.81B, United States/Canada segment decrease of 12% to EUR3.15B, Rest of the World segment decrease of 4% to EUR872.1M. Net income also reflects Selling/General/Admin. Expense - Balanci increase of 11% to EUR567.3M (expense).
Equity composition
12/11, 10% Stock dividend. 12/2011, Scrip Issue, 1 new share for every 10 shares held @ EUR0.1 (Factor: 1.1), 12/2012, Scrip Issue, 1 new B shares for every 20 B shares held (Factor: 1.05). 1/2016, 2-for-1 stock split (Factor: 2).
Industry: | Biopharmaceuticals |
C/ Jesús y María, 6
BARCELONA
BARCELONA 08022
ES
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com